About Tabula Rasa Healthcare (NASDAQ:TRHC)
Tabula Rasa HealthCare, Inc. (Tabula Rasa), formerly CareKinesis, Inc., is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs. It also provides risk adjustment services, which help its clients to properly characterize a patient's acuity, or severity of health condition, and optimize the associated payments for care. The Company serves approximately 100 healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. Its products and services are built around the Medication Risk Mitigation Matrix, or MRM Matrix.
Industry, Sector and Symbol:
- Industry: Medical Software & Technology Services
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: NASDAQ:TRHC
- CUSIP: N/A
- Web: www.tabularasahealthcare.com
- Debt-to-Equity Ratio: 0.47%
- Current Ratio: 0.73%
- Quick Ratio: 0.66%
Sales & Book Value:
- Forward P/E Ratio: 714.60
- P/E Growth: 27.63
- Annual Sales: $94.06 million
- Price / Sales: 6.78
- Cash Flow: $0.39 per share
- Price / Cash: 90.50
- Book Value: $3.48 per share
- Price / Book: 10.27
- Trailing EPS: ($0.17)
- Net Income: $-6,250,000.00
- Net Margins: -2.27%
- Return on Equity: -5.58%
- Return on Assets: -3.49%
- Employees: 241
- Outstanding Shares: 17,850,000
Frequently Asked Questions for Tabula Rasa Healthcare (NASDAQ:TRHC)
What is Tabula Rasa Healthcare's stock symbol?
Tabula Rasa Healthcare trades on the NASDAQ under the ticker symbol "TRHC."
How were Tabula Rasa Healthcare's earnings last quarter?
Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) released its quarterly earnings data on Monday, November, 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.02. The company earned $33.27 million during the quarter, compared to the consensus estimate of $31.76 million. Tabula Rasa Healthcare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The firm's revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.06 earnings per share. View Tabula Rasa Healthcare's Earnings History.
When will Tabula Rasa Healthcare make its next earnings announcement?
Where is Tabula Rasa Healthcare's stock going? Where will Tabula Rasa Healthcare's stock price be in 2017?
6 equities research analysts have issued 12-month price objectives for Tabula Rasa Healthcare's stock. Their forecasts range from $16.00 to $41.00. On average, they anticipate Tabula Rasa Healthcare's share price to reach $28.33 in the next year. View Analyst Ratings for Tabula Rasa Healthcare.
What are Wall Street analysts saying about Tabula Rasa Healthcare stock?
Here are some recent quotes from research analysts about Tabula Rasa Healthcare stock:
- 1. According to Zacks Investment Research, "Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company's cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. " (11/10/2017)
- 2. Piper Jaffray Companies analysts commented, "Tabula Rasa reported another strong revenue quarter but guided 1Q17 profitability slightly below expectations in order to ramp up operations to meet the needs of new large accounts. We believe this investment will be leveraged over time because it's supporting the growth of higher margin business, and will also gain efficiency over time. We are reiterating OW, and raising PT to $19 from $18." (3/14/2017)
- 3. Stifel Nicolaus analysts commented, "On March 13, 2017, Tabula Rasa (TRHC) announced strong results for 4Q16 and full year. 2017 guidance for revenue and adjusted-EBITDA was established in and around expectations but fell slightly short of our modeling. Management provided an update of the operations and key customers along with quarterly remarks and an update on new business. We believe TRHC is a company with unique products that will have an interested audience in coming years given unrelenting healthcare trends that are agnostic to political party. TRHC is Buy-rated. Raise target to $19 (from $17) based on combination of price-to-sales and EV-EBITDA multiples." (3/14/2017)
Who are some of Tabula Rasa Healthcare's key competitors?
Some companies that are related to Tabula Rasa Healthcare include Evolent Health (EVH), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), Craneware plc (CRW), NantHealth (NH), Simulations Plus (SLP), Fluidigm Corporation (FLDM), Complete Genomics (GNOM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Greenway Health (GWAY).
Who are Tabula Rasa Healthcare's key executives?
Tabula Rasa Healthcare's management team includes the folowing people:
- Calvin H. Knowlton Ph.D., Chairman of the Board, Chief Executive Officer, Co-Founder (Age 67)
- Orsula Voltis Knowlton, President, Co-Founder, Director (Age 49)
- Brian W. Adams, Chief Financial Officer (Age 36)
- Samira K. Beckwith, Director (Age 64)
- Glen R. Bressner, Independent Director (Age 56)
- Dennis K. Helling, Independent Director (Age 68)
- Daniel C. Lubin, Independent Director (Age 57)
- Bruce H. Luehrs, Independent Director (Age 63)
When did Tabula Rasa Healthcare IPO?
(TRHC) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Wells Fargo Securities, UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Baird and Stifel were co-managers.
Who owns Tabula Rasa Healthcare stock?
Tabula Rasa Healthcare's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hood River Capital Management LLC (4.23%), Pier Capital LLC (0.87%), Wasatch Advisors Inc. (0.85%), EAM Investors LLC (0.82%), Allianz Asset Management GmbH (0.80%) and Paradigm Capital Management Inc. NY (0.45%). Company insiders that own Tabula Rasa Healthcare stock include Calvin H Knowlton, Glen R Bressner, Gordon Tunstall, Joann M Durham and Orsula V Knowlton. View Institutional Ownership Trends for Tabula Rasa Healthcare.
Who sold Tabula Rasa Healthcare stock? Who is selling Tabula Rasa Healthcare stock?
Tabula Rasa Healthcare's stock was sold by a variety of institutional investors in the last quarter, including Hood River Capital Management LLC. Company insiders that have sold Tabula Rasa Healthcare company stock in the last year include Calvin H Knowlton, Gordon Tunstall and Orsula V Knowlton. View Insider Buying and Selling for Tabula Rasa Healthcare.
Who bought Tabula Rasa Healthcare stock? Who is buying Tabula Rasa Healthcare stock?
Tabula Rasa Healthcare's stock was purchased by a variety of institutional investors in the last quarter, including Pier Capital LLC, Wasatch Advisors Inc., EAM Investors LLC, Allianz Asset Management GmbH, Cadence Capital Management LLC, JPMorgan Chase & Co., California Public Employees Retirement System and Rhumbline Advisers. View Insider Buying and Selling for Tabula Rasa Healthcare.
How do I buy Tabula Rasa Healthcare stock?
Shares of Tabula Rasa Healthcare can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tabula Rasa Healthcare's stock price today?
One share of Tabula Rasa Healthcare stock can currently be purchased for approximately $35.73.
How big of a company is Tabula Rasa Healthcare?
Tabula Rasa Healthcare has a market capitalization of $615.08 million and generates $94.06 million in revenue each year. The company earns $-6,250,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tabula Rasa Healthcare employs 241 workers across the globe.
How can I contact Tabula Rasa Healthcare?
Tabula Rasa Healthcare's mailing address is 228 Strawbridge Dr Ste 100, MOORESTOWN, NJ 08057-4600, United States. The company can be reached via phone at 866-648-2767 or via email at [email protected]
MarketBeat Community Rating for Tabula Rasa Healthcare (NASDAQ TRHC)MarketBeat's community ratings are surveys of what our community members think about Tabula Rasa Healthcare and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Tabula Rasa Healthcare (NASDAQ:TRHC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.83)|
|Consensus Price Target: ||$28.33 (20.70% downside)|
Consensus Price Target History for Tabula Rasa Healthcare (NASDAQ:TRHC)
Analysts' Ratings History for Tabula Rasa Healthcare (NASDAQ:TRHC)
(Data available from 11/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/7/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$35.00||N/A|
|11/1/2017||First Analysis||Initiated Coverage||Overweight||$41.00||N/A|
|10/19/2017||Wells Fargo & Company||Boost Price Target||Market Perform||$21.00 -> $27.00||N/A|
|10/17/2017||Robert W. Baird||Reiterated Rating||Outperform||$22.00 -> $30.00||N/A|
|8/8/2017||Chardan Capital||Boost Price Target||Buy -> Buy||$19.50 -> $21.00||High|
|7/14/2017||Stifel Nicolaus||Reiterated Rating||Buy||$16.00||Low|
Earnings History and Estimates Chart for Tabula Rasa Healthcare (NASDAQ:TRHC)
Earnings History by Quarter for Tabula Rasa Healthcare (NASDAQ TRHC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/12/2018|| || || || || || || || |
|11/6/2017||Q3 2017||$0.06||$0.08||$31.76 million||$33.27 million||View||N/A|
|8/7/2017||Q2 2017||$0.06||$0.06||$27.84 million||$29.70 million||View||Listen|
|5/1/2017||Q1 2017||$0.06||$0.04||$26.00 million||$27.70 million||View||Listen|
|3/13/2017||Q4 2016||$0.11||$0.10||$25.53 million||$27.30 million||View||N/A|
|11/9/2016||Q316||$0.03||$0.06||$22.35 million||$24.17 million||View||Listen|
Earnings Estimates for Tabula Rasa Healthcare (NASDAQ:TRHC)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Tabula Rasa Healthcare (NASDAQ:TRHC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tabula Rasa Healthcare (NASDAQ TRHC)
Insider Ownership Percentage: 45.80%
Institutional Ownership Percentage: 28.41%
Insider Trades by Quarter for Tabula Rasa Healthcare (NASDAQ TRHC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/18/2017||Orsula V Knowlton||Insider||Sell||8,000||$26.68||$213,440.00|| |
|9/13/2017||Orsula V Knowlton||Insider||Sell||8,000||$22.10||$176,800.00|| |
|8/16/2017||Calvin H Knowlton||CEO||Sell||8,000||$17.21||$137,680.00|| |
|7/19/2017||Orsula V Knowlton||Insider||Sell||8,000||$14.20||$113,600.00|| |
|6/14/2017||Orsula V. Knowlton||Insider||Sell||8,000||$14.02||$112,160.00|| |
|6/12/2017||Gordon Tunstall||Director||Sell||22,759||$13.76||$313,163.84|| |
|5/18/2017||Glen R Bressner||Director||Buy||7,500||$11.96||$89,700.00|| |
|5/17/2017||Orsula V Knowlton||Insider||Sell||8,000||$11.94||$95,520.00|| |
|10/4/2016||Glen R Bressner||Director||Buy||8,500||$12.00||$102,000.00|| |
|10/4/2016||Joann M Durham||Major Shareholder||Sell||4,070||$12.00||$48,840.00|| |
Latest Headlines for Tabula Rasa Healthcare (NASDAQ TRHC)
Tabula Rasa Healthcare (NASDAQ TRHC) Chart for Tuesday, November, 21, 2017